• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Stopped Out on Johnson & Johnson but Willing to Buy it Lower

Stand aside for now.
By BRUCE KAMICH
Mar 03, 2021 | 12:20 PM EST
Stocks quotes in this article: JNJ, MRK

In his first "Executive Interview" segment of Mad Money Tuesday evening, Jim Cramer talked to Alex Gorsky, chairman and CEO of Johnson & Johnson (JNJ) .

On Tuesday, J&J announced a partnership with rival Merck (MRK) to ramp up their one-dose Covid vaccine even faster.

Now that Johnson & Johnson's vaccine is approved for use, it was only fitting to partner with Merck to bring 30 million doses by the end of March and over 100 million doses in the first half of 2021. Gorsky said the cooperation between J&J, Merck, and the federal government, under the defense production act, has never been better.

J&J plans go well past U.S. borders, however. Gorsky said they're committed to working with Europe and the developing world to ensure that everyone on the planet has access to vaccines as quickly as possible. The fact that Johnson & Johnson's vaccine is only a single dose and doesn't require special refrigeration are key to these efforts.

When asked when the pandemic will be over, Gorsky said the next several months will be critical. He said we can't let our guard down or relax restrictions too early, but he's optimistic that by summer we'll have made significant progress.

Let's check and see what sort of progress the stock of JNJ is making.

In this updated daily bar chart of JNJ, below, we can see that prices made a high at the end of January and have subsequently declined despite the news of the approval of its Covid-19 vaccination. Prices are now trading below the 50-day moving average line which is cresting. The slightly rising 200-day moving average line intersects just above $150 and could be tested in the weeks ahead.

The On-Balance-Volume (OBV) line is showing weakness since the beginning of the new year and tells us there is a shift from aggressive buying to aggressive selling.

The Moving Average Convergence Divergence (MACD) oscillator is poised to cross below the zero line to generate an outright sell signal.

In this weekly bar chart of JNJ, below, we can see the price action of the past three years. JNJ has seen a number of pullbacks or corrections in its slow march higher. Prices could weaken to retest the slightly rising 40-week moving average line that intersects down around $150.

The weekly OBV line looks a little "toppy" over the past two months and the MACD oscillator has narrowed significantly and is close to a downside crossover.

In this daily Point and Figure chart of JNJ, below, we can see a potential downside price target in the $147 area.

In this weekly close only Point and Figure chart of JNJ, below, we can see that the software is projecting a possible $213 price target on the upside.

Bottom line strategy: The last time we reviewed the charts of JNJ was on January 27 and we recommended "Continue to hold longs recommended in December. Raise sell stops to $160. Our price targets are $181, the round number of $200 and then the $234 area." With the price weakness we have seen I will assume that traders have been stopped out around $160. Stand aside for now and let's see if prices reach the $147 area to try the long side again.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Healthcare | Pharmaceuticals | Mad Money | Executive Interview | Coronavirus

More from Investing

Market's 'Superficial' Highs Are Only Skin Dip

James "Rev Shark" DePorre
Apr 9, 2021 4:36 PM EDT

You can't call this market overbought when so much of it isn't participating.

Pinterest: Double Top or Breakout Pending?

Bruce Kamich
Apr 9, 2021 3:00 PM EDT

What would I do in this case? Here's the logical choice.

I'm Continuing to Build a Position in Skillz

Timothy Collins
Apr 9, 2021 2:24 PM EDT

SKLZ shows explosion moves to the upside when it emerges from the oversold area.

Royalty Pharma Shows Promise

Bruce Kamich
Apr 9, 2021 1:10 PM EDT

Here's how traders should play RPRX right now.

Making the Best of the Peculiar Market Action

James "Rev Shark" DePorre
Apr 9, 2021 12:17 PM EDT

Trading in biotech stocks and a particular SPAC play are on my mind.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • 08:05 AM EDT BOB LANG

    Bitcoin vs. Gold: Which Should You Invest In Now?

    Read my article TheStreet here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login